Several studies have shown that CCA patients with abundant CD8+ T cell infiltration, significant PD-L1 expression, high-level microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), and high tumor mutational burden (TMB) exhibit better sensitivity to immunotherapy (45, 46). The gene discussed is CD8A; the disease is mismatch repair cancer syndrome 1.